Briacell Therapeutics Corp (BCT.TO) is seeing a positive trend, closing up 2.28% in the latest trading session. This reflects a growing confidence among investors.
In this session, Briacell's stock rose to CA$4.04, driven by ongoing developments in the biotech sector, especially in immunotherapy.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$48.54M
52W high
$27.20
52W low
$3.68
1W change
+6.60%
Beta
1.54
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 275.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+275.2% Upside
Current Price
C$5.33
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
64.8%
Annualized
90-Day Vol
87.4%
Annualized
Trend (90d)
-43.4%
Annualized drift
90d Mean
C$4.56
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.06 | C$4.05 โ C$6.33 |
| 60 trading days | C$4.81 | C$3.50 โ C$6.59 |
| 90 trading days | C$4.56 | C$3.10 โ C$6.72 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Briacell's progress in immunotherapy, as recent advancements could impact future stock performance.
Briacell Therapeutics Corp Market Cap Reaches CA$33.9 Million
With a market cap of CA$33.9 million, Briacell operates in a specialized area of the biotech industry, focusing on personalized cancer immunotherapies.
Bull case
Briacell's stock rise may be due to increasing investor confidence in its innovative cancer treatments. This boost follows positive clinical results and strategic moves by the company.
Bear case
Even with the recent gains, investors should stay cautious. The biotech sector can be unpredictable, and any setbacks in clinical trials or regulatory approvals could affect stock performance.
Recent Performance Overview
Briacell's stock has shown resilience, with a 2.28% increase in the last session. This positive movement aligns with a broader trend in the biotech sector, where innovative solutions are attracting investor interest.
Market Sentiment and Future Outlook
The market's reaction to Briacell's advancements in personalized immunotherapy is encouraging. Investors are hopeful about future growth, especially as the company continues to make progress in clinical trials and product development. For more details on Briacell's stock performance, visit our BCT.TO page.
Key Developments to Watch
As Briacell moves forward, important developments such as upcoming clinical trial results and corporate announcements will play a crucial role in shaping investor sentiment. Keep an eye on these factors, as they could significantly influence the stock's direction. For ongoing updates, check our Briacell Therapeutics Corp stock page.
Advertisement
